Arthritis Rheumatol 2022 doi: 10.1002/art.42280
In this investigation bimekizumab was associated with a sustained ACR50 improvement. This was highlighted following the attempt to describe the long-term safety, tolerability, and efficacy of up to three years of bimekizumab treatment in PsA patients
Adult patients with active PsA completing the double and dose-blind periods of the BE ACTIVE randomized controlled trial could enrol in the open-label extension (OLE) at
Week 48, after which patients received bimekizumab 160 mg every four weeks. Safety and efficacy results are presented through 152 Weeks, presenting a safety profile which was consistent with previous reports, with no new safety signals identified.